F-star Therapeutics - FSTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $35.00
  • Forecasted Upside: 535.21 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.51
▲ +0.19 (3.57%)

This chart shows the closing price for FSTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New F-star Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FSTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FSTX

Analyst Price Target is $35.00
▲ +535.21% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for F-star Therapeutics in the last 3 months. The average price target is $35.00, with a high forecast of $35.00 and a low forecast of $35.00. The average price target represents a 535.21% upside from the last price of $5.51.

This chart shows the closing price for FSTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in F-star Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2022HC WainwrightDowngradeBuy ➝ NeutralLow
6/23/2022SVB LeerinkDowngradeOutperform ➝ Market PerformLow
6/23/2022LaidlawDowngradeBuy ➝ HoldLow
6/23/2022LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
6/23/2022William BlairDowngradeOutperform ➝ Market PerformLow
5/17/2022HC WainwrightInitiated CoverageBuy$35.00Medium
3/17/2022HC WainwrightReiterated RatingBuy$35.00High
11/18/2021LADENBURG THALM/SH SHLower TargetBuy$27.00 ➝ $15.00High
11/12/2021OppenheimerBoost TargetOutperform$30.00 ➝ $33.00Medium
10/22/2021William BlairReiterated RatingBuyMedium
9/21/2021HC WainwrightReiterated RatingBuy$35.00Low
8/17/2021SVB LeerinkLower TargetOutperform$39.00 ➝ $35.00High
7/8/2021SVB LeerinkInitiated CoverageOutperform$39.00High
6/8/2021B. RileyInitiated CoverageBuy$28.00High
5/18/2021HC WainwrightInitiated CoverageBuy$35.00Medium
4/15/2021OppenheimerInitiated CoverageOutperform$30.00High
4/8/2021William BlairInitiated CoverageOutperformHigh
3/24/2021LaidlawInitiated CoverageBuy$32.00High
3/1/2021HC WainwrightInitiated CoverageBuy$35.00Low
12/2/2020LADENBURG THALM/SH SHInitiated CoverageBuyHigh
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/13/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/12/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/10/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
F-star Therapeutics logo
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $5.51
Low: $5.21
High: $5.53

50 Day Range

MA: $5.57
Low: $4.56
High: $6.27

52 Week Range

Now: $5.51
Low: $2.07
High: $6.76

Volume

91,908 shs

Average Volume

209,018 shs

Market Capitalization

$121.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of F-star Therapeutics?

The following Wall Street sell-side analysts have issued reports on F-star Therapeutics in the last twelve months: HC Wainwright, LADENBURG THALM/SH SH, Laidlaw, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for FSTX.

What is the current price target for F-star Therapeutics?

1 Wall Street analysts have set twelve-month price targets for F-star Therapeutics in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 535.2%. HC Wainwright has the highest price target set, predicting FSTX will reach $35.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $35.00 for F-star Therapeutics in the next year.
View the latest price targets for FSTX.

What is the current consensus analyst rating for F-star Therapeutics?

F-star Therapeutics currently has 5 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FSTX, but not buy more shares or sell existing shares.
View the latest ratings for FSTX.

What other companies compete with F-star Therapeutics?

How do I contact F-star Therapeutics' investor relations team?

F-star Therapeutics' physical mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company's listed phone number is 441223497400 and its investor relations email address is [email protected] The official website for F-star Therapeutics is www.f-star.com. Learn More about contacing F-star Therapeutics investor relations.